Shubham Atal

Shubham Atal

Auto-generated profile, based on publicly available information

Shubham Atal

Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2020 in Pharmaceutical Medicine
Verified
Journal Article
Open access
PDF file
SAShubham Atal
Shubham Atal
ZFZeenat Fatima
Zeenat Fatima
At present, there are no proven agents for treatment of coronavirus disease (COVID-19). The available evidence has not allowed guidelines to clearly recommend any drugs outside the context of clinical trials. The novel coronavirus SARS-CoV-2 that causes COVID-19 invokes a hyperinflammatory state driven by multiple cells and mediators like interleukin (IL)-1, IL-6, IL-12, and IL-18, tumor necrosis factor alpha (TNFα), etc. Considering the proven role of cytokine dysregulation in causing this hyperinflammation in the lungs with IL-6 being a key driver, particularly in seriously ill COVID-19 patients, it is crucial to further explore selective cytokine blockade with drugs like the IL-6 inhibitors tocilizumab, sarilumab, and siltuximab. These targeted monoclonal antibodies can dampen the downstream IL-6 signaling pathways, which can lead to decreased cell proliferation, differentiation, oxidative stress, exudation, and improve clinical outcomes in patients with evident features of cytokine-driven inflammation like persistent fever, dyspnea and elevated markers. Preliminary evidence has come for tocilizumab from some small studies, and interim analysis of a randomized controlled trial; the latter also being available for sarilumab. International guidelines do include IL-6 inhibitors as one of the options available for severe or critically ill patients. There has been increased interest in evaluating these drugs with a series of clinical trials being registered and conducted in different countries. The level of investigation though perhaps needs to be further intensified as there is a need to focus on therapeutic options that can prove to be ‘life-saving’ as the number of COVID-19 fatalities worldwide keeps increasing alarmingly. IL-6 inhibitors could be one such treatment option, with generation of more evidence and completion of a larger number of systematic studies.

1 January 2016 in Pharmacognosy Research
Verified
Journal Article
Open access
PDF file
SAShubham Atal
Shubham Atal
SASarjana Atal
Sarjana Atal
SVSavita Vyas
Savita Vyas
PPPradeep Phadnis
Pradeep Phadnis
Background: Diabetes mellitus is the most rampant metabolic pandemic of the 21 st century. Piperine, the chief alkaloid of Piper nigrum (black pepper) is widely used in alternative and complementary therapies has been extensively studied for its bio-enhancing property. Objective: To evaluate the bio-enhancing effect of piperine with metformin in lowering blood glucose levels in alloxan-induced diabetic mice. Materials and Methods: Piperine was isolated from an extract of fruits of P. nigrum. Alloxan-induced (150 mg/kg intraperitoneal) diabetic mice were divided into four groups. Group I (control 2% gum acacia 2 g/100 mL), Group II (metformin 250 mg/kg), Group III (metformin and piperine 250 mg/kg + 10 mg/kg), and Group IV (metformin and piperine 125 mg/kg + 10 mg/kg). All the drugs were administered orally once daily for 28 days. Blood glucose levels were estimated at day 0, day 14, and end of the study (day 28). Results: The combination of piperine with therapeutic dose of metformin (10 mg/kg + 250 mg/kg) showed significantly more lowering of blood glucose level as compared to metformin alone on both 14 th and 28 th day (P < 0.05). Piperine in combination with sub-therapeutic dose of metformin (10 mg/kg + 125 mg/kg) showed significantly more lowering of blood glucose as compared to control group and also showed greater lowering of blood glucose as compared to metformin (250 mg/kg) alone. Conclusion: Piperine has the potential to be used as a bio-enhancing agent in combination with metformin which can help reduce the dose of metformin and its adverse effects.

13 December 2022 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
ASAjay Kumar Shukla
Ajay Kumar Shukla
SAShubham Atal
Shubham Atal
ABAditya Banerjee
Aditya Banerjee
RJRatinder Jhaj
Ratinder Jhaj
SBSadasivam Balakrishnan
Sadasivam Balakrishnan
NKNilima Kshirsagar
Nilima Kshirsagar
India has seen more than 43 million confirmed cases of COVID-19 as of April 2022, with a recovery rate of 98.8%, resulting in a large section of the population including the healthcare workers (HCWs), susceptible to develop post COVID sequelae. This study was carried out to assess the nature and prevalence of medical sequelae following COVID-19 infection, and risk factors, if any. This was an observational, multicenter cross-sectional study conducted at eight tertiary care centers. The consenting participants were HCWs between 12 and 52 weeks post discharge after COVID-19 infection. Data on demographics, medical history, clinical features of COVID-19 and various symptoms of COVID sequelae was collected through specific questionnaire. Mean age of the 679 eligible participants was 31.49 ± 9.54 years. The overall prevalence of COVID sequelae was 30.34%, with fatigue (11.5%) being the most common followed by insomnia (8.5%), difficulty in breathing during activity (6%) and pain in joints (5%). The odds of having any sequelae were significantly higher among participants who had moderate to severe COVID-19 (OR 6.51; 95% CI 3.46–12.23) and lower among males (OR 0.55; 95% CI 0.39–0.76). Besides these, other predictors for having sequelae were age (≥45 years), presence of any comorbidity (especially hypertension and asthma), category of HCW (non-doctors vs doctors) and hospitalisation due to COVID-19. Approximately one-third of the participants experienced COVID sequelae. Severity of COVID illness, female gender, advanced age, co-morbidity were significant risk factors for COVID sequelae. This work is a part of 10.13039/501100001411 Indian Council for Medical Research (ICMR)- Rational Use of Medicines network. No additional financial support was received from ICMR to carry out the work, for study materials, medical writing, and APC.

13 July 2020 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
RJRajnish Joshi
Rajnish Joshi
SAShubham Atal
Shubham Atal
ZFZeenat Fatima
Zeenat Fatima
SBSadasivam Balakrishnan
Sadasivam Balakrishnan
SSSwati Sharma
Swati Sharma
AJAnkur Joshi
Ankur Joshi
Providing scheduled consultations to persons with diabetes during the COVID-19 induced lockdowns posed a major challenge. With the clinicians occupied in COVID management, a strategy of using telemedicine and engaging a team of para-clinical doctors was devised. Telephonic follow up consults were given and diabetes care was efficiently delivered.

29 October 2020 in Diabetology International
Verified
Journal Article
Closed access
PDF file
SAShubham Atal
Shubham Atal
ZFZeenat Fatima
Zeenat Fatima
SSSakshi Singh
Sakshi Singh
SBSadasivam Balakrishnan
Sadasivam Balakrishnan
RJRajnish Joshi
Rajnish Joshi

16 October 2012
Verified
Journal Article
Closed access
SAShubham Atal
Shubham Atal
RARajendra P Agrawal
Rajendra P Agrawal
SVSavita Vyas
Savita Vyas
PPPradeep Phadnis
Pradeep Phadnis
NRNiket Rai
Niket Rai